Filing Analysis
Arcturus Therapeutics announced it will present clinical data regarding its ARCT-810 mRNA therapy at the 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism. The presentation focuses on the impact of the therapy on dietary intake and biochemical data in patients with Ornithine Transcarbamylase Deficiency.
📋 Key Facts
- Presentation titled 'Impact of ARCT-810 mRNA Therapy on Dietary Intake and Biochemical Data in Adolescents and Adults with Ornithine Transcarbamylase Deficiency'.
- Event: 2026 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism in Helsinki, Finland.
- Company expects to communicate additional data and a regulatory plan for the program later this quarter.
Arcturus Therapeutics Holdings Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026, and provided a corporate update via press release.
🚩 Red Flags
- None identified in the text provided; standard cautionary language regarding clinical trial success and cash burn is present but typical for biotech.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026
- Filing date: August 6, 2026
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Forward-looking statements include pipeline developments for ARCT-032 and ARCT-810.
Arcturus Therapeutics entered into a strategic collaboration with Thermo Fisher Scientific to provide CDMO and CRO services for the development of ARCT-032, an investigational mRNA therapeutic for cystic fibrosis. The agreement includes significant service commitments totaling up to $80 million in combined manufacturing and research value.
🚩 Red Flags
- Potential loss of manufacturing exclusivity: Thermo Fisher holds a right to negotiate exclusive commercial manufacturing rights upon product approval.
📋 Key Facts
- Entered into a Master Services Agreement (MSA) and Project Agreement with Thermo Fisher Scientific Inc. on June 26, 2026.
- Thermo Fisher will contribute up to $40 million of clinical manufacturing services for ARCT-032.
- Arcturus will engage PPD, Inc. (a Thermo Fisher affiliate) for up to $40 million in CRO services.
- The MSA includes an initial term of five years with automatic one-year renewals.
- Thermo Fisher may receive exclusive commercial manufacturing rights upon regulatory approval of ARCT-032, subject to future negotiations.
Arcturus Therapeutics Holdings Inc. reported the results of its 2026 annual meeting of stockholders held on June 5, 2026. Stockholders elected the Board of Directors, approved executive compensation on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual meeting held on June 5, 2026, with a quorum of 21,435,189 shares present out of 28,423,069 entitled to vote.
- Eight directors were elected to the Board: Dr. Peter Farrell, Joseph E. Payne, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui.
- The 'say-on-pay' advisory resolution for executive compensation was approved with 15,254,240 votes in favor.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 21,378,017 votes in favor.
Arcturus Therapeutics appointed Dennis Mulroy as its new Chief Financial Officer effective May 1, 2026, while simultaneously reporting Q1 2026 financial results. Mulroy succeeds Joe Roberts, who had been serving as interim principal financial officer since December 2025.
🚩 Red Flags
- Multiple 8-K items (2.02, 5.02, 7.01) filed simultaneously.
- The company has been operating with an interim principal financial officer since December 2025.
📋 Key Facts
- Dennis Mulroy (71) appointed CFO with a base salary of $520,000 and a 40% target bonus.
- Mulroy was granted 100,000 stock options vesting over four years.
- Joe Roberts will continue as the Company’s Controller and interim principal accounting officer.
- The filing includes Q1 2026 financial results and updates on the ARCT-032 and ARCT-810 clinical programs.
- Mulroy previously served as CFO of AnaptysBio, Inc. and La Jolla Pharmaceutical Company.
Arcturus Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update on its clinical pipeline and strategic partnerships.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025.
- Provided clinical updates on ARCT-032, including plans for a Phase 2, 12-week study.
- Discussed regulatory strategy for ARCT-810, including upcoming Type C meetings with regulators.
- Highlighted ongoing collaborations with CSL Seqirus for COVID-19 and flu programs.
- Confirmed ongoing development of a self-amplifying mRNA pandemic influenza vaccine under contract with BARDA.
- Management indicated that general and administrative expenses are expected to decrease slightly.
Arcturus Therapeutics announced the amicable departure of CFO Andy Sassine, effective December 31, 2025, and his resignation from the Board. The company has appointed Controller Joe Roberts as interim Principal Financial Officer and Principal Accounting Officer.
🚩 Red Flags
- Sudden departure of the CFO and Board member simultaneously.
- Appointment of an 'interim' financial lead suggests a transition period rather than a permanent replacement being ready.
📋 Key Facts
- CFO Andy Sassine to depart on an amicable basis effective December 31, 2025.
- Sassine resigned from the Board of Directors effective December 11, 2025.
- The Board size was reduced from nine members to eight following the resignation.
- Severance package for Sassine includes 12 months of base salary, bonus eligibility, attorney's fees reimbursement, and 18 months of COBRA premiums.
- Unvested stock options for Sassine will accelerate and become immediately exercisable upon separation.
- Joe Roberts (Controller since March 2024) appointed as interim PFO and IAO effective December 12, 2025.
- Interim PFO/IAO compensation includes a base salary of $219,580 plus up to 20% bonus eligibility.
Arcturus Therapeutics Holdings Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025, and provided a corporate update via press release.
🚩 Red Flags
- Forward-looking statements note uncertainty regarding cash position, expected cash burn, and runway.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 10, 2025.
- The filing includes forward-looking statements regarding pipeline candidates ARCT-032 and ARCT-810.
- Mention of ongoing collaboration with CSL Seqirus for COVID-19 and flu programs.
Arcturus Therapeutics reported interim Phase 2 clinical results for its cystic fibrosis therapy (ARCT-032) and provided updates on regulatory hurdles for its KOSTAIVE vaccine. The company is also engaged in ongoing litigation against AbbVie Inc. regarding trade secret misappropriation.
🚩 Red Flags
- Regulatory setback: The FDA has changed its stance on the data package required for KOSTAIVE, now requiring additional clinical endpoint efficacy studies rather than just a single-dose indication.
- Ongoing litigation against major industry players (AbbVie) which introduces legal uncertainty and potential costs.
📋 Key Facts
- Released interim Phase 2 data for LUNAR-CF (ARCT-032), an inhaled mRNA therapy for cystic fibrosis, on October 22, 2025.
- Filed a lawsuit against AbbVie Inc. and Capstan Therapeutics on September 23, 2025, alleging trade secret misappropriation and breach of contract.
- The FDA requested a delay in the BLA submission for KOSTAIVE to provide additional advice; specifically, the FDA now requires additional data from a clinical endpoint efficacy study.
- CSL Seqirus submitted an MAA for KOSTAIVE to the UK MHRA, with approval expected in Q1 2026.
Arcturus Therapeutics announced that its partner, Meiji Seika Pharma Co., Ltd., has launched a new presentation of the KOSTAIVE® mRNA vaccine in Japan targeting Omicron sub-lineages. This development relates to an existing distribution agreement between Arcturus and CSL Seqirus/Meiji.
📋 Key Facts
- Meiji Seika Pharma Co., Ltd. launched a new presentation of KOSTAIVE®, a self-amplifying mRNA vaccine against COVID-19.
- The product targets the SARS-CoV-2 Omicron sub-lineage JN.1 variant XEC.
- Non-clinical studies show neutralizing antibodies against variants JN.1, XEC, LP.8.1, XFG, and NB.1.8.1.
- Arcturus has an existing distribution agreement (dated April 11, 2023) with CSL Seqirus for the Japanese market.
Arcturus Therapeutics announced that its partner, Meiji Seika Pharma Co., Ltd., received manufacturing and marketing approval in Japan for a new presentation of the KOSTAIVE® (ARCT-2301) mRNA vaccine targeting Omicron sub-lineages. The product is being distributed in Japan via an agreement with CSL Seqirus.
📋 Key Facts
- Meiji Seika Pharma received Japanese approval for a new presentation of KOSTAIVE® (ARCT-2301).
- The vaccine targets SARS-CoV-2 Omicron sub-lineages, specifically JN.1 and XEC, with non-clinical data showing activity against LP.8.1, XFG, and NB.1.8.1.
- The product is supplied as a two-dose vial formulation.
- Distribution in Japan is handled by CSL Seqirus (a part of CSL Limited) under an agreement dating back to April 2023.
Arcturus Therapeutics Holdings Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided a corporate update via press release.
🚩 Red Flags
- Forward-looking statements express uncertainty regarding cash burn, runway, and the ability to decrease general and administrative expenses.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025.
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- Key pipeline programs mentioned in forward-looking statements include ARCT-032 (CF study), ARCT-810, and pandemic flu studies.
- Partnership mentions: CSL Seqirus (COVID-19/flu) and Meiji Seika Pharma (Japan).
Arcturus Therapeutics announced positive Phase 2 interim results for its mRNA therapeutic candidate, ARCT-810, intended to treat OTC deficiency. The company also released a corporate presentation regarding the clinical progress of this candidate.
📋 Key Facts
- Announced positive Phase 2 interim results for ARCT-810 in patients with OTC deficiency.
- ARCT-810 is an mRNA therapeutic designed to restore urea cycle activity and prevent hyperammonemia crises.
- The company issued a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) on June 30, 2025.
Arcturus Therapeutics Holdings Inc. held its 2025 annual meeting of stockholders on June 6, 2025. The results included the election of nine directors and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual meeting held on June 6, 2025.
- Quorum was established with 22,006,524 shares present out of 27,120,603 total shares entitled to vote.
- All nine nominees for the Board of Directors were elected to serve until the 2026 annual meeting.
- The non-binding 'say-on-pay' advisory resolution regarding executive compensation was approved with 18,472,131 votes in favor.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Arcturus Therapeutics Holdings Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided a corporate update regarding its clinical pipeline.
🚩 Red Flags
- Forward-looking statements highlight risks regarding cash burn, runway, and the ability to achieve clinical milestones or milestone payments from partners.
📋 Key Facts
- Reported financial results for the fiscal quarter ended March 31, 2025.
- Provided updates on ARCT-032 Phase 2 CF study enrollment and interim data timing.
- Provided updates on ARCT-810 Phase 2 OTC deficiency study enrollment.
- Discussed progress of KOSTAIVE regulatory filings in the US and UK.
- Referenced ongoing partnerships with CSL Seqirus regarding COVID-19 and flu programs.
Arcturus Therapeutics Holdings Inc. issued an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024, alongside a corporate update.
🚩 Red Flags
- Forward-looking statements highlight risks regarding cash position, expected cash burn, and runway.
- Uncertainty regarding net profit payments from CSL Seqirus for sales of KOSTAIVE.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Filing date: March 6, 2025.
- The filing includes a press release (Exhibit 99.1) detailing financial performance and pipeline updates.
- Pipeline focus mentioned in forward-looking statements: ARCT-032 (CF study), ARCT-810 (OTC deficiency study), and KOSTAIVE.
Arcturus Therapeutics announced its financial results for the quarter ended September 30, 2024, and provided a corporate update via press release. The filing serves as a formal notice of the earnings release under Item 2.02.
🚩 Red Flags
- Forward-looking statements highlight risks regarding cash position, expected cash burn, and runway (standard for biotech but noted).
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Key pipeline programs mentioned include ARCT-032, ARCT-810, and KOSTAIVE.
Arcturus Therapeutics Holdings Inc. has furnished an updated corporate presentation via its website to comply with Regulation FD disclosure requirements.
📋 Key Facts
- The company posted an updated corporate presentation on August 13, 2024.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The information in the presentation is not considered 'filed' for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.
Arcturus Therapeutics announced its financial results for the quarter ended June 30, 2024, and provided a corporate update via press release. The filing serves as a formal notice of the earnings release rather than containing new material agreements or structural changes.
🚩 Red Flags
- Forward-looking statements regarding cash burn, runway, and collection of accounts receivables from CSL suggest potential liquidity monitoring is required by investors.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 5, 2024.
- The company provided updates on its pipeline, specifically mentioning ARCT-032 and ARCT-810.
- Mention of partnered programs with CSL Seqirus (COVID-19 and flu programs).
- Discussion of the commercialization outlook for Kostaive®.
Arcturus Therapeutics Holdings Inc. announced the appointment of Dr. Moncef Slaoui to its Board of Directors, effective June 19, 2024.
📋 Key Facts
- Dr. Moncef Slaoui has been appointed as a member of the Board of Directors.
- His term lasts until the next annual meeting of stockholders or until a successor is elected.
- Compensation for Dr. Slaoui will be consistent with other non-employee directors as disclosed in the 2024 Proxy Statement.
- Dr. Slaoui has extensive leadership experience, including serving as Chairman of Vaccines at GSK and advisor to the White House's Operation Warp Speed.
Arcturus Therapeutics held its annual meeting of stockholders on June 14, 2024, where shareholders approved the election of eight directors and an amendment to the company's equity incentive plan. The meeting also resulted in the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2024.
🚩 Red Flags
- Increase in equity incentive plan shares (2 million additional shares) can lead to future dilution of existing shareholders.
📋 Key Facts
- Annual meeting held on June 14, 2024.
- Stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing the maximum number of shares available by 2,000,000 to a total of 10,750,000 shares.
- Eight directors were elected to serve until the 2025 annual meeting: Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, and Dr. John H. Markels.
- Shareholders approved 'say-on-pay' (non-binding advisory resolution on executive compensation).
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Arcturus Therapeutics issued an 8-K to announce its financial results for the quarter ended March 31, 2024, and provided a corporate update regarding its clinical pipeline and partnerships.
🚩 Red Flags
- Forward-looking statements regarding cash burn, runway, and the timing of accounts receivable collection from CSL.
📋 Key Facts
- Report date: May 8, 2024
- Reporting period: Quarter ended March 31, 2024 (Note: Text contains a likely typo stating 2023, but context implies current results)
- The filing includes updates on the Kostaive commercialization and European Marketing Authorization application.
- Updates provided for pipeline candidates including ARCT-032 (LUNAR-CF) and ARCT-810.
- Discussion of ongoing clinical studies for ARCT-2303 (Omicron XBB.1.5 variant) and ARCT-2138 (LUNAR-FLU).
Arcturus Therapeutics Holdings Inc. has dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm and appointed Deloitte & Touche LLP, effective April 5, 2024. This change follows a period where EY issued an adverse opinion on the company's internal control over financial reporting.
🚩 Red Flags
- Auditor change combined with a previously disclosed adverse opinion on internal controls.
- Material weaknesses identified in IT general controls (ITGCs).
- Material weaknesses identified in controls over the review of costs for collaboration arrangements.
📋 Key Facts
- Dismissal of Ernst & Young LLP (EY) as independent auditor effective April 5, 2024.
- Appointment of Deloitte & Touche LLP as the new independent auditor for fiscal year ending December 31, 2024.
- EY's report on internal control over financial reporting as of Dec 31, 2023, contained an adverse opinion.
- Management identified material weaknesses in IT general controls (ITGCs) and controls over performance obligation costs for FY2023.
- The company stated there were no disagreements with EY regarding accounting principles or auditing scope.
Arcturus Therapeutics announced that a bivalent version of its COVID-19 vaccine (ARCT-2301) met the primary endpoint in a Phase III clinical study conducted by Meiji Seika Pharma in Japan. This development relates to the existing partnership with Meiji and CSL Seqirus for distribution in the Japanese market.
📋 Key Facts
- Meiji Seika Pharma announced that Kostaive® (ARCT-2301) met its primary endpoint in a Phase III clinical study for booster vaccination in Japan.
- The vaccine is a self-amplifying mRNA vaccine against COVID-19.
- Arcturus has an existing distribution agreement with Meiji and CSL Seqirus for the Japanese market.
Arcturus Therapeutics issued an 8-K/A to amend its previous earnings release due to non-cash revenue adjustments identified during the fiscal year-end audit. The adjustment resulted in a $3.2 million decrease in collaboration revenue for both Q4 and full-year 2023.
🚩 Red Flags
- Revenue restatement due to audit adjustments (non-cash revenue adjustments).
- Decrease in reported collaboration revenue for both quarterly and annual periods.
📋 Key Facts
- Collaboration revenue for FY 2023 decreased from $160.9 million to $157.7 million.
- Q4 2023 collaboration revenue decreased from $28.2 million to $25.0 million.
- Updated net loss for FY 2023 is $29.7 million ($1.12 per share) vs previously reported figures.
- Updated net loss for Q4 2023 is $11.7 million ($0.44 per share).
- The adjustment increased deferred revenue by $3.2 million on the balance sheet.
- Cash, cash equivalents, and runway expectations remain unchanged.
Arcturus Therapeutics issued an 8-K to announce its financial results for the quarter ended December 31, 2023, and provided a corporate update. The filing serves as a vehicle to furnish the press release containing these results.
🚩 Red Flags
- Forward-looking statements highlight risks regarding cash position, expected cash burn, and runway.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Quarter ended December 31, 2023
- The filing includes an update on clinical pipeline programs including ARCT-032 and ARCT-810
- Mentions partnered programs with CSL Seqirus (COVID-19 and flu)
Arcturus Therapeutics announced the resignation of its Senior Vice President of Finance and Corporate Controller, Keith C. Kummerfeld, effective March 15, 2024. The company has appointed Joseph Roberts to succeed him as Controller.
🚩 Red Flags
- Departure of a high-level finance executive (SVP level) can sometimes signal internal friction, though the stated reason is 'another opportunity'.
📋 Key Facts
- Keith C. Kummerfeld (SVP of Finance and Corporate Controller) is resigning on March 15, 2024.
- Reason for departure: To pursue another opportunity.
- Joseph Roberts has been promoted from Assistant Controller to Controller.